{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6a5f74b61af15f4e64120a0f?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?  ","description":"<p>The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel (zamto-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)?&nbsp;</p><p><br></p><p><em>This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</em>&nbsp;</p>","author_name":"Scientific Education Support"}